Stockreport

AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease

Avenue Therapeutics, Inc.  (ATXI) 
Last avenue therapeutics, inc. earnings: 8/14 07:30 am Check Earnings Report
PDF TAIPEI, March 10, 2023 /PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: AT [Read more]